The present invention relates to methods of treating an animal having a non-cancerous medical condition that is ameliorated by treatment with a trypsin inhibitor, the method comprising obtaining a biological sample from the animal； testing the sample to obtain a trypsin concentration, wherein, if the trypsin concentration is above the upper limit of the normality, the animal is treated for a suitable period of time by administering to the animal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the compound N-α-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-phenylalanine-4-ethoxycarbonylpiperazide, the stereoisomers, racemic mixtures, metabolite, pharmaceutically acceptable salt, crystal, or any combination thereof. In an embodiment, the non-cancerous medical condition is an inflammatory digestive disease selected from the group consisting of pancreatitis, gastritis, irritable bowel syndrome, and inflammatory bowel disease. In an embodiment, the pharmaceutical composition is in an orally administrable form.
